# Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez

Page: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-70-ash-2025-myeloid-neoplasm-roundup-with-dr-curtis-lachowiez
Text version: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-70-ash-2025-myeloid-neoplasm-roundup-with-dr-curtis-lachowiez.md
Podcast: [Blood Cancer Talks](https://stenobird.com/podcast/blood-cancer-talks-5570002)
Published: 2026-02-27T11:54:06+00:00
Episode link: https://share.transistor.fm/s/71fb798f
Audio file: https://media.transistor.fm/71fb798f/9197dc55.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-70-ash-2025-myeloid-neoplasm-roundup-with-dr-curtis-lachowiez
Duration seconds: 3413

## Resource

In this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management. 1. PARADIGM Trial (Plenary Session, Abstract 6) Fathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6. https://doi.org/10.1182/blood-2025-6 ClinicalTrials.gov: NCT04801797 2. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654) Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654. ClinicalTrials.gov: NCT05520567 3. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45) Azevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45. Original publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. https://doi.org/10.1200/JCO.23.01911 ClinicalTrials.gov: NCT04140487 4. PRISM-AML Score (Abstract 453) Lachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453. Interactive Calculator: https://prism-aml.com 5. Additional Studies Referenced in Discussion • VIALE-A Trial: DiNardo CD, et al. Azacitidine and venetoc…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-70-ash-2025-myeloid-neoplasm-roundup-with-dr-curtis-lachowiez/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-70-ash-2025-myeloid-neoplasm-roundup-with-dr-curtis-lachowiez.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.